Instead, standard regimens used for other cancers, such as rhabdomyosarcoma, germ cell tumor, or soft tissue sarcoma, are most often the treatment paradigms chosen for specific DICER1-associated cancers. This evidence concerns the gene DICER1 and soft tissue sarcoma.